Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy

Completed

Conditions: Exposure During Pregnancy

Interventions: Drug: No intervention

First Posted Date: 2023-04-07

Last Posted Date: 2023-09-25

Lead Sponsor: Takeda

Target Recruit Count: 7

Registration Number: NCT05803200

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

Conditions: Hunter Syndrome

First Posted Date: 2023-04-03

Last Posted Date: 2024-04-04

Lead Sponsor: Takeda

Registration Number: NCT05795361

Locations: 🇺🇸
Childrens Hospital Orange County, Anaheim, California, United States
🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
The Regents of the University of California, Oakland, California, United States

and more 25 locations

Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)

First Posted Date: 2023-03-15

Last Posted Date: 2023-04-06

Lead Sponsor: Takeda

Registration Number: NCT05770219

A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain

Withdrawn

Conditions: Metachromatic Leukodystrophy (MLD)

Interventions: Other: No Intervention

First Posted Date: 2023-03-06

Last Posted Date: 2024-01-12

Lead Sponsor: Takeda

Registration Number: NCT05755568

Locations: 🇪🇸
Hospital Clinico Universitario de Santiago, Santiago de Compostela, A Coruna, Spain
🇪🇸
Hospital Universitario y Politecnico La Fe, Valencia, Spain
🇪🇸
Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain

and more 7 locations

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Phase 2

Recruiting

Conditions: Primary Immunodeficiency Diseases (PID)

Interventions: Biological: TAK-881
Biological: HYQVIA

First Posted Date: 2023-03-06

Last Posted Date: 2024-10-07

Lead Sponsor: Takeda

Target Recruit Count: 75

Registration Number: NCT05755035

Locations: 🇺🇸
University of California Irvine Medical Center, Irvine, California, United States
🇺🇸
Allergy and Asthma Clinical Research, Walnut Creek, California, United States
🇺🇸
National Jewish Medical And Research Center, Denver, Colorado, United States

and more 38 locations

A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

Completed

Conditions: Leukemia

Interventions: Other: No Intervention

First Posted Date: 2023-02-24

Last Posted Date: 2023-03-02

Lead Sponsor: Takeda

Target Recruit Count: 1769

Registration Number: NCT05743465

Locations: 🇺🇸
Takeda, Cambridge, Massachusetts, United States

A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

Recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: No intervention

First Posted Date: 2023-02-21

Last Posted Date: 2023-09-05

Lead Sponsor: Takeda

Target Recruit Count: 50

Registration Number: NCT05735327

Locations: 🇵🇱
Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Lublin, Lubelskie, Poland
🇵🇱
Dolnoslskie Centrum Onkologii, Pulmonologii i Hematologii, Wroclaw, Dolnoslskie, Poland
🇵🇱
Szpital Kliniczny im. Heliodora Swiecickiego UM wPoznaniu., Poznan, Wielkopolskie, Poland

and more 9 locations

A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)

Withdrawn

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Other: No Intervention

First Posted Date: 2023-02-21

Last Posted Date: 2023-10-23

Lead Sponsor: Takeda

Registration Number: NCT05737849

Locations: 🇨🇳
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College, Beijing, China

A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

Recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Brigatinib

First Posted Date: 2023-02-10

Last Posted Date: 2025-01-06

Lead Sponsor: Takeda

Target Recruit Count: 200

Registration Number: NCT05721950

Locations: 🇨🇳
Department of Oncology, Shanghai pulmonary hospital, Shanghai, Shanghai, China

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Phase 2

Active, not recruiting

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)

Interventions: Biological: TAK-755

First Posted Date: 2023-02-06

Last Posted Date: 2024-12-10

Lead Sponsor: Takeda

Target Recruit Count: 40

Registration Number: NCT05714969

Locations: 🇺🇸
University of Florida Shands, Gainesville, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 25 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy